anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses one kind of polypeptide with p38 kinase inhibiting activity and its application. The polypeptide has one of the following amino acid residue sequence: 1. SEQ ID No. 1 in the sequence list; 2. SEQ ID No. 2 in the sequence list; and 3, the amino acid residue sequence of SEQ ID No. 1 or SEQ ID No. 2 through substitution, deletion and/or addition of one or several amino acid residues and with protein possessing p38 kinase inhibiting activity related function. The polypeptide of the present invention can enter to cell to inhibit p38 kinase activity specifically and block the signal transmission of p38 channel, and can inhibit inflammation reaction.
INTRODUCTION: Anterior sacral meningocele is a rare congenital disorder, occurring isolated or in syndromic disease.
CASE REPORT: A 15-year-old patient who complained of abdominal pain and urinary dysfunction was managed surgically. Imaging diagnosed a giant presacral meningocele and agenesis of the coccyx.
DISCUSSION: The presentation of sacral meningocele can be poorly symptomatic, which is why some patients are diagnosed late. Sometimes, diagnosis is suggested by non-specific abdominal symptoms or complications. Abdominal-pelvic radiological examination and lumbar spine MRI are essential, and treatment must be surgical. There are several surgical approaches, but currently no consensus.
CONCLUSION: An unusual huge presacral cystic mass in a young patient may be isolated or part of a syndrome, and can be asymptomatic for a long time, leading to late diagnosis. The surgical approach should be based on multidisciplinary discussion. We operated on a giant anterior sacral meningocele in a child using a posterior approach, with a satisfactory result.
1,167,469. Plasminogen activator. FARBENFABRIKEN BAYER A.G. 20 Feb., 1968 [2 March, 1967], No. 8218/68. Heading A5B. A plasminogen activator is isolated by (i) treating stromata of erythrocytes, preferably human, with an aqueous acidic solution, e.g. aqueous HC1 or H 2 SO 4 ; (ii) extracting the activator from the aqueous solution into an organic phase; and (iii) isolating the activator from the organic phase. After step (i), and before step (ii), insoluble solids may be removed from the solution, and/or the solution may be dialysed to remove dialysable impurities. The activator may be extracted from the aqueous solution into an organic phase comprising or consisting of a phenol and/or a chlorophenol and subsequently extracted from the organic phase into aqueous solution by the addition of water and an excess of a non-polar organic solvent, e.g. isopropyl ether-chloroform. The activator may be further purified by dialysis, adsorption, chromatography, isoelectrical precipitation or gel filtration and the activator may be isolated by lyophilization or precipitation. The plasminogen activator may be used in the treatment and prophylaxis of thromboses and embolisms in the form of an injectable solution.
Subarachnoid hemorrhage is a devastating sequela of aneurysm rupture. Because it disproportionately affects younger patients, the population impact of hemorrhagic stroke from subarachnoid hemorrhage is substantial. Secondary brain injury is a significant contributor to morbidity after subarachnoid hemorrhage. Initial hemorrhage causes intracranial pressure elevations, disrupted cerebral perfusion pressure, global ischemia, and systemic dysfunction. These initial events are followed by two characterized timespans of secondary brain injury: the early brain injury period and the delayed cerebral ischemia period. The identification of varying microglial phenotypes across phases of secondary brain injury paired with the functions of microglia during each phase provides a basis for microglia serving a critical role in both promoting and attenuating subarachnoid hemorrhage-induced morbidity. The duality of microglial effects on outcomes following SAH is highlighted by the pleiotropic features of these cells. Here, we provide an overview of the key role of microglia in subarachnoid hemorrhage-induced secondary brain injury as both cytotoxic and restorative effectors. We first describe the ontogeny of microglial populations that respond to subarachnoid hemorrhage. We then correlate the phenotypic development of secondary brain injury after subarachnoid hemorrhage to microglial functions, synthesizing experimental data in this area.
PURPOSE:To give strong adhesive property and its durability between both a compound and a material without processing acidification or the like in the case of adhesively attaching a dental adhesive correcting material e.g. bonding material, PMMA resin, etc., by mixing prescribed amounts of a polymer compound having a hydroxyl group, polymer compound having an acid radical, and an amino compound. CONSTITUTION:A primer composition contains 0.5 to 90wt.% water, 5 to 90wt.% polymer compound having a hydroxyl groups, 0.1 to 90wt.% polymer compound having an acid radical and 0.01 to 30wt.% amino compound having an acid radical. The water in use is preferable distilled water (or purified water) or ion exchange water (or deionized water). The polymer compound, having a hydroxyl group, is especially preferably polymerized monomer having unsaturated radical polymerizable with the hydroxyl group, for instance, acryloil radical or allyl radical. The polymer compound in use having the acid radical is especially preferably polymerized product of monomer having, for instance, unsaturated radical polymerizable with carboxyl radical phosphoric acid radical, etc., for instance, acryloyl radical or allyl radical. The amino compound having the acid radical is an amino compound, for instance, having carboxyl radical and carboaldehyde radical or the like.
Following a total of 15 sessions of electro-physical agent treatment, exercise training, 5 days a week for 3 weeks, each session lasting 45 minutes, and traditional physiotherapy 2 days a week for 3 weeks, a total of 6 times applied to the trapezius muscle in the neck area with 0% tension. Kinesiotape will be applied in the form of (I). The tape will be applied twice a week in total, staying for 3 days and leaving one day free after each application.
The invention belongs to the field of medicines, and specifically relates to an arctigenin micro-emulsion enteric soft capsule preparation, and a preparation method thereof. The enteric soft capsules are composed of contents containing arctigenin micro-emulsion concentrated liquid and enteric capsule shells. The capsules can be dissolved in intestines. With the capsules, bioavailability of arctigenin is improved, and irritation to the stomach is reduced. The capsules can be directionally released in intestines, and has the advantages of high stability and good sustained-release effect. The capsule preparation has a good medical application prospect.
BACKGROUND: Capsular contracture is one of the most frequent indications for revision following breast augmentation. Management goals focus on restoring breast aesthetics and minimizing subsequent recurrence of capsular contracture. As new data emerge, close review of the data are merited to build evidence-based clinical guidelines to inform surgical practice and management of capsular contracture.
METHODS: A systematic review of the MEDLINE, Embase, and Cochrane Database of Systematic Reviews databases was conducted to characterize the surgical management of capsular contracture in revision breast augmentations. The primary endpoint was capsular contracture recurrence rate.
RESULTS: The review was conducted in November of 2021. Primary search revealed 14,163 results. Initial screening by title left 1223 articles. Abstract review left 90 articles for full-text review, of which 34 were ultimately included and were all observational in nature.
CONCLUSIONS: Capsular contracture management remains an important topic, with limited high-level evidence for establishing clear evidence-based treatment guidelines. Although more evidence is required to assess the effects of capsulectomy, implant exchange, and plane change, these appear to be useful mechanisms for reducing recurrent capsular contracture. There is more evidence regarding the use of acellular dermal matrix, although this still requires long-term follow-up studies. New developments regarding textured implants limit the revision breast augmentation surgeon to smooth devices.
There have been postmarketing reports of overdose with piperacillin and tazobactam. The majority of those events experienced, including nausea, vomiting, and diarrhea, have also been reported with the usual recommended dosages. Patients may experience neuromuscular excitability or seizures if higher than recommended doses are given intravenously (particularly in the presence of renal failure) [see Warnings and Precautions ( 5.5)] . 

Treatment should be supportive and symptomatic according to the patient's clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis. Following a single 3.375 g dose of piperacillin and tazobactam, the percentage of the piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively [see Clinical Pharmacology (12)] .
Emotional stress, particularly when a patients inhibits their experiences and feelings, contributes to physical symptoms. However, primary care patients with medically unexplained symptoms are rarely assessed for the stress and emotions in an comprehensive manner. The goal of this study is to test the feasibility and acceptability of providing an experiential assessment interview that targets emotional and stressful experiences in primary care with medically unexplained physical symptoms. In this randomized, controlled trial, the investigators will compare an interview condition to a wait-list control condition. The interview will review patients health history, psychosocial history, make links between the two, and help patients identify and express emotions related to conflicts or victimization. The investigators hypothesize that helping individuals first identify the links between their stress and symptoms will likely increase their awareness and endorsement of the link between stress and physical symptoms, including a willingness to engage in stress management techniques. It is also expected that helping raise an individual's awareness about their symptoms, followed by an experience and expression of unexpressed emotions is likely to influence their physical symptoms and psychological status.
Matrix metalloproteinases (MMPs) have a role in driving neuroinflammation in infectious as well as non-infectious diseases; however, recent reports have potentiated the role of microRNAs in regulating MMPs at post-transcriptional levels, leading to dysregulation of crucial MMP functions like tissue remodelling, blood brain barrier integrity, etc. In present study, microRNAs regulating MMPs (MMP2 and MMP3) were selected from database search followed by literature support. Expression of these microRNAs i.e., hsa-miR-495-3p, hsa-miR-132-3p and hsa-miR-21-5p was assessed by RT-PCR and the protein levels of MMPs were assessed by ELISA in the cerebrospinal fluid (CSF) of tuberculous meningitis (TBM) patients, healthy controls (HC) and non-infectious neuroinflammatory disease (NID) patients. The expression of hsa-miR-495-3p and hsa-miR-132-3p showed downregulation in TBM while hsa-miR-21-5p was overexpressed as compared to healthy controls. Moreover, MMP levels were found to be deranged with a significant increase in MMP3 levels in the TBM and NID patients compared to HC group. These observations highlight dysregulated microRNAs (hsa-miR-495-3p, hsa-miR-21-5p and hsa-miR-132-3p) levels might impair the levels of MMPs (MMP2 and MMP3) leading to neuroinflammation in TBM and NID population. These findings can further be applied to target these microRNAs for developing newer treatment modalities for better complication management.
589854 A computer-implemented method and an apparatus for facilitating selection of desirable choices are disclosed. In the method relative scores are generated in a processing device for a first group of choices in response to results from a plurality of forced choice comparisons by a plurality of informed domain representatives. The plurality of forced choice comparisons each include a selection of one choice from a pair of choices and the selections form the results for generating the relative scores. At an input device, measurements of at least two characteristics of each of a second group of choices are received and in a computing device, predicted relative scores for the individual ones of the second group of choices are calculated using the measurements of the at least two characteristics of each of the second group of choices in a model of the relative scores of the first group of choices. The predicted relative scores to communicate the predicted relative scores to facilitate selection of desirable choices are outputted via an output device. Further disclosed is a computer-implemented method for assisting a person to maintain a predetermined diet. In this method a minimum and maximum relative score number effective for maintaining a predetermined diet over a period of time are determined in a processing device. A relative score number is calculated for each of a number of possible food serving choices by fitting at least two characteristics of the possible food serving choices to a model generated from results of a plurality of forced choice comparisons of sample food choices by a plurality of informed domain representatives. The plurality of forced choice comparisons each include a selection of one food choice from a pair of food choices and the selections form the results for generating the model. Food serving choices are identified in a computing device that will provide an aggregated total relative score number between the determined minimum and maximum relative score number; and a diet plan using the identified food serving choices to thereby assist the person to maintain the predetermined diet is outputted via an output device.
Dosage must be individualized and closely monitored during up-titration. Prior to initiation of metoprolol succinate extended-release tablets, stabilize the dose of other heart failure drug therapy. The recommended starting dose of metoprolol succinate extended-release tablets is 25 mg once daily for two weeks in patients with NYHA Class II heart failure and 12.5 mg once daily in patients with more severe heart failure. Double the dose every two weeks to the highest dosage level tolerated by the patient or up to 200 mg of metoprolol succinate extended-release. Initial difficulty with titration should not preclude later attempts to introduce metoprolol succinate extended-release. If patients experience symptomatic bradycardia, reduce the dose of metoprolol succinate extended-release. If transient worsening of heart failure occurs, consider treating with increased doses of diuretics, lowering the dose of metoprolol succinate extended-release tablets or temporarily discontinuing it. The dose of metoprolol succinate extended-release tablets should not be increased until symptoms of worsening heart failure have been stabilized.
Halitosis is an unpleasant odor that emanating from the mouth. A recent metanalysis shows worldwide trend towards a rise in halitosis prevalence. Studies show halitosis returns in a week after treatment with photodynamic therapy (PDT). Probably, bacteria residing in the periodontal sulcus could recolonize the dorsum of the tongue. To date, there are no study in adult population that associate halitosis and periodontal treatment with follow-up evaluation. The aim of this randomized, controlled clinical trial was to treat oral halitosis in healthy adults with photodynamic therapy associated with periodontal treatment and follow them up for 3 months. The participants (n=40) with halitosis will be randomized into two groups: G1-treatment with photodynamic therapy (n = 20) or G2-cleaning of the tongue with a tongue scraper (n = 20). Halitosis were evaluated measuring volatile sulfur compounds using gas chromatography After the treatments, a second evaluation will be performed, along with a microbiological analysis (qPCR) for the identification of the bacteria T. denticola. The evaluation of halitosis and the microbiological analysis will be repeated. After that, patients will receive periodontal treatment. The participants will return after 1 week and three months for an additional evaluation. Quality of life will be measured by Oral Health Impact Profile (OHIP-14) Comparisons will be made with ANOVA test, with the level of significance of 5 %. This protocol will determine the effectiveness of phototherapy regarding the reduction of halitosis in adults.
Subjects will be recruited and stratified into BMI groups: \<18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and \>30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
The present invention relates to a user interface method of a virus safety passport application for facility entry. There is an effect of preventing the spread of an infectious disease inside a facility, and simultaneously, when a person who has entered the facility has been determined to be an infected person, quickly specifying the other people who have entered in the same time zone in the same facility to give an alarm and take follow-up measures. To this end, the present invention proposes a user interface method for, when an entrant enters after a temperature check, authenticating an entry event and a facility. When the entrant's smartphone recognizes an NFC tag that stores a facility identification code, a user screen on which a virus safety passport application is to be installed is called. An entry authentication user screen is called by installing and then executing the virus safety passport application on the entrant's smartphone. When an input means presses an authentication request button on the entry authentication user screen, the mobile phone number of the entrant's smartphone is obtained by executing an SIM access module of the virus safety passport application, and then an authentication completion user screen is displayed while the facility identification code of the NFC tag and the entrant's mobile phone number are transmitted to a management server.
Economic disadvantage has been found to be associated with delayed cognitive and language development, and mental health symptoms such as aggression, anxiety of children. Chronic cumulative stressors of poverty disrupt their attention, emotional and behavioural regulation, that would further lead to negative impact in early development. As their parents are also affected by stress, they often become unresponsive, harsh and inconsistent in child discipline, resulting in a chronic stress to their children. Mindfulness is defined as paying attention purposefully and non-judgmentally to the present moment. It has been shown to improve attention, promote exposure to unpleasant experiences, facilitate cognitive change, and enhance the ability to cope with life stress. Mindfulness training has been established as an evidence-based intervention for people suffering from various chronic conditions. Its application in a family context, including parents and children, is just beginning. The purpose of this study is to assess the effectiveness of a family-based mindfulness intervention (FBMI) in reducing parental stress and promoting child adjustment. Intervention effectiveness will be tested by conducting a randomized controlled trial comparing a group receiving FBMI to a wait-list control group. Children aged five and their parents will be recruited to participate in the study. Eligible families will be recruited, stratified by level of economically disadvantage, behaviour problem scores, and parental stress, and then randomly assigned to the two groups. Intervention groups will be conducted by instructors with professional training. Children in the intervention group are expected to show improvements in cognitive and language development, behaviour problems, attention and emotional/behavior regulation, and physiological stress (reduced cortisol and heart rate variability), compared with the waitlist control group. Parents are expected to show improvements in physiological and psychological stress, and mindfulness, compared with the waitlist control group. The proposed project will be the first of its kind to use mindfulness training in a family context in Hong Kong. It is also unique as it examines the effectiveness of a mindfulness-based intervention with multiple outcome measures related to stress, combining self-reported measures with biomarkers, and psychological tests. For model building and theory development, this study may shed light on assessing the change mechanisms for promoting child learning, emotional and behavioural regulation, particularly in relation to studies of stress physiology and economically disadvantaged families. The results may not only benefit in Hong Kong but also those in other Chinese societies and countries.
The present invention discloses an organic compound which assists in minimizing the appearance of or removing unwanted skin growths and discolorations without damaging or scarring the skin. The organic compound of the present invention include a mineral from the family of pyrophyllite and organic apple cider vinegar. The ratio of the bentonite to the vinegar is between about 1:1 to 1:1.5, by weight (grams) to by volume (milliliters). The mineral is preferably bentonite or montmorillonite. A method for making and applying the organic compound is also presently disclosed This method includes a first step of providing a mineral from the family of pyrophyllite. In a second step, organic apple cider vinegar is provided. The mineral is then mixed with the vinegar to form a paste. The paste is then applied to areas of the skin upon which there are growths. Preferably, between about 0.18 to about 0.21 grams of the paste should be applied to about every 0.5 cm of the growth.
PURPOSE OF REVIEW: There is a growing recognition of plaque erosion as a cause of acute coronary syndrome. This review aims to examine the potential involvement of T cells in this process.
RECENT FINDINGS: Immune-vascular interactions have been identified in the development of plaque erosions. Up to one-third of eroded plaques show evidence of active immune infiltration, with the presence of T cells. We propose that microerosions may frequently occur in association with the infiltration of T cells and macrophages in early atherosclerotic lesions. Healing of erosions could trigger the deposition of excessive extracellular matrix. The pro-inflammatory and cytotoxic actions of T cells, along with reduced endothelial integrity and other mechanisms, may subsequently give rise to clinical symptoms. To gain a better understanding of the role of T cells in plaque erosion, it is crucial to develop improved models for conducting controlled experiments and to study atherosclerosis in younger individuals.